
AJUNTAMENT D'ALCOI
Website

Generalitat Valenciana
Website

Ayuntamiento de Valencia
Website

Cicloplast
Website

Ayuntamiento de Onil
Website

Anarpla
Website

Ayuntamiento de Mislata
Website

nlWA, North London Waste Authority
Website

Ayuntamiento de Salinas
Website

Zicla
Website

Fondazione Ecosistemi
Website

PEFC
Website

ALQUIENVAS
Website

DIPUTACI� DE VAL�NCIA
Website

AYUNTAMIENTO DE REQUENA
Website

UNIVERSIDAD DE ZARAGOZA
Website

OBSERVATORIO CONTRATACIÓN PÚBLICA
Website

AYUNTAMIENTO DE PAIPORTA
Website

AYUNTAMIENTO DE CUENCA
Website

BERL� S.A.
Website

CM PLASTIK
Website

TRANSFORMADORES INDUSTRIALES ECOL�GICOS

INDUSTRIAS AGAPITO
Website

RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors
Multi-target, especially dual-target, drug design has become a popular research field for cancer treatment. Development of small molecule dual-target inhibitors through hybridization strategy can provide highly potent and selective anticancer agents. In this study, three series of quinazoline derivatives bearing a benzene-sulfonamide moiety were designed and synthesized as dual EGFR/CAIX inhibitors. All the synthesized compounds were evaluated against epidermoid carcinoma (A431) and non-small cell lung cancer (A549 and H1975) cell lines, which displayed weak to potent anticancer activity. In particular, compound 8v emerged as the most potent derivative against mutant-type H1975?cells, which exhibited comparable activity to osimertinib. Importantly, 8v exhibited stronger anti-proliferative activity than osimertinib against H1975?cells under hypoxic condition. Kinase inhibition studies indicated that 8v showed excellent inhibitory effect on EGFRT790M enzyme, which was 41 times more effective than gefitinib and almost equal to osimertinib. Mechanism studies revealed that 8v exhibited remarkable CAIX inhibitory effect comparable to acetazolamide and significantly inhibited the expression of p-EGFR as well as its downstream p-AKT and p-ERK in H1975?cells. Notably, 8v was found to inhibit the expression of CAIX and its upstream HIF-1? in H1975?cells under hypoxic condition. Molecular docking was also performed to gain insights into the ligand-binding interactions of 8v inside EGFRWT, EGFRT790M and CAIX binding sites.

» Author: Bin Zhang, Zhikun Liu, Shengjin Xia, Qingqing Liu, Shaohua Gou
» Publication Date: 15/04/2021
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es
